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Abstract: An increasing number of infections of highly pathogenic avian inﬂ  uenza virus 
(H5N1) in humans has been reported in South-East Asia and other areas of the world. High 
mortality (60%) of this viral infection and its pathosis of systemic infection are features of 
this new human disease. Moreover, there is great concern that this avian H5N1 virus could 
cause a pandemic of new inﬂ  uenza in humans, once it acquires the ability for human to human 
transmission. To prevent such highly contagious infectious diseases as inﬂ  uenza, it is essential 
to prepare effective vaccines. Especially in the case of new inﬂ  uenza virus, we cannot predict the 
strain which will cause the pandemic. In such a situation, a vaccine that induces cross-protective 
immunity against variant viruses is extremely important. However currently used parenteral 
seasonal inﬂ  uenza vaccine is strain-speciﬁ  c, and is less effective against variant viruses. In order 
to overcome the weakness of current vaccines we need to learn from the immune responses 
induced by natural infection with inﬂ  uenza viruses. In the case of mucosally acquired acute 
respiratory infection such as inﬂ  uenza, mucosal immunity induced by natural infection plays 
important role in protection against the infection, as mucosal secretory IgA antibody plays an 
important role in cross-protection. In this review we describe the advantages and development 
of mucosal vaccine against highly pathogenic H5N1 inﬂ  uenza viruses.
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Inﬂ  uenza virus and its infection signal
Inﬂ  uenza is a contagious acute respiratory disease of birds and mammals caused by 
infection of the upper respiratory tract by viruses of the family Orthomyxoviridae. 
Types A and type B infect humans and cause respiratory symptoms and also encepha-
lopathy in infants. Recently it has been reported that infection by highly pathogenic 
inﬂ  uenza viruses (HPIV) and the avian inﬂ  uenza virus (H5N1) in humans can be 
fatal. In cases where infection sites were not restricted to the respiratory system, it 
spread systemically including the gastrointestinal (GI) tract.1 Although most human 
H5N1 infections have been caused by the direct transmission of virus from infected 
poultry, there is fear that a pandemic could result if subsequent transmission of H5N1 
virus occurred between infected humans.2 Therefore, there is an urgent and important 
public health need to develop effective vaccines against this highly pathogenic strain 
of avian inﬂ  uenza virus.
Annual epidemics of inﬂ  uenza are caused when the antigenic properties of the 
viral surface proteins hemagglutinin (HA) and neuraminidase (NA) are altered. HA 
is involved in binding of the virus to sialic acids on the surface of susceptible cells.3 
NA cleaves terminal sialic acid residues from carbohydrate moieties on the surfaces of 
infected cells, promoting the release of progeny viruses from infected cells. It has been 
shown that both HA and NA are among the most protective of the various viral proteins 
against inﬂ  uenza when immunized with plasmid DNAs encoding HA and NA.4Therapeutics and Clinical Risk Management 2009:5 126
Hasegawa et al
Inﬂ  uenza virus has single-stranded RNA as its genome, 
and this single-stranded RNA is recognized as an infection 
signal by host cells through Toll-like receptor 7 (TLR-7).5 
In the course of viral replication, double-stranded RNA is 
produced, which is recognized by TLR-3 as an infection 
signal. Thus, inﬂ  uenza virus is recognized by host immune 
cells at the very early stage of infection by the host through 
pathogen signals, and these receptors and the host immune 
system initiate the mucosal and systemic immune system 
against present and future viral infection. By verifying a 
series of events occurring at the infection site, we use our 
increased understanding of the immune response to develop 
and apply strategies to combat inﬂ  uenza viral infection.
Innate immunity and adjuvant effect
Innate immunity is a set of nonspeciﬁ  c mechanisms that 
constitute the body’s naturally occurring immune response 
to infection by microbes at any site. In inﬂ  uenza virus infec-
tion, the upper respiratory mucosal surface is the effector 
site of the innate immune system. The mechanical barrier 
of the mucosal epithelium, surface mucus, secretion of anti-
microbial peptides such as defensins, secretion of type I and 
II interferons (IFNs), natural killer cells, and complement 
factor all play important roles in innate immunity at the 
respiratory mucosa (Figure 1). Among these, the IFN 
response is required to signal viral infection. During inﬂ  uenza 
virus infection, genomic single-stranded RNA, and double-
stranded RNA produced during viral replication, have been 
implicated as the molecular signals of infection that trigger 
IFN production.
The innate immune system senses viral infection by 
recognizing a variety of viral components, including double-
stranded (ds) RNA, and triggering antiviral responses. The 
cytoplasmic helicase protein retinoic-acid-inducible protein I 
(RIG-I, also known as Ddx58) and melanoma differentiation-
associated gene 5 (MDA5, also known as Iﬁ  h1 or Helicard) 
have been implicated in recognition of viral dsRNA. Viral 
dsRNA binds to RIG-I and MDA5 in the cytoplasm, which 
leads to activation of IFN regulatory factors.6 In vitro studies 
suggest that RIG-I and MDA5 recognize both RNA viruses, 
and polyinosine-polycytidylic acid (poly(I:C)), a synthetic 
dsRNA analog. RIG-I is essential for the production of 
IFNs in response to RNA viruses, including paramyxovirus, 
inﬂ  uenza virus, and Japanese encephalitis virus, whereas 
MDA5 is critical for the detection of picornavirus.6 The 
recognition of viral infection by the innate immune system 
Figure 1 Defence mechanism at mucosal site, innate and adaptive immunity.
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bridges the transition between innate and adaptive immune 
responses. This is a particularly important facet of innate 
immunity involved in mucosal immune responses. We can 
take advantage of the mucosal innate immune response to 
enhance vaccine efﬁ  cacy, which we will discuss later in 
this review.
Among the several innate immune receptors, the 
Toll-like receptor family plays a central role in the 
recognition of viral nucleic acid. This recognition leads to 
the induction of type I IFN. We previously demonstrated 
that the synthetic double-stranded RNA (dsRNA) 
poly(I:C), a TLR-3 agonist, has mucosal adjuvant activ-
ity when co-administered intranasally with an inﬂ  uenza 
HA vaccine, and increases both the mucosal and systemic 
humoral response, resulting in complete protection against 
challenge by homologous avirulent (H1N1) and highly 
pathogenic (H5N1) inﬂ  uenza viruses in mice.7,8 Sloat 
and Cui9 also reported that mice immunized intranasally 
with recombinant anthrax protective antigen adjuvanted 
with poly(I:C) developed strong systemic and mucosal 
anti-anthrax antigen responses with lethal toxin neutraliza-
tion activity. Thus, the signals conducted by innate immune 
receptors work as adjuvants which act as a bridge between 
innate immunity and acquired immunity.
Mucosal vaccine
Seasonal inﬂ  uenza vaccines are prepared based on the 
prediction of the expected strain of epidemic of the next 
season. These are parenterally injected vaccines which 
does not prevent the infection itself, which reduce the 
severity and complications after the infection. Parenteral 
vaccines can induce the neutralizing IgG antibody in the 
serum but they cannot induce the secretory IgA antibody 
which acts on the mucosal surface. Secretory IgA antibod-
ies on the mucosal membrane surface are highly effective 
for preventing infection because they react on the surface 
of the mucosal membrane before the pathogens attach to 
the epithelial cell surface, which is the ﬁ  rst target of inﬂ  u-
enza viral infection. Moreover, serum IgG antibodies are 
less effective against drifted viral strains because they act 
more speciﬁ  cally than secretory IgA antibodies. Secretory 
IgA antibodies have cross-protective effects against vari-
ant strains of the inﬂ  uenza virus. The exact mechanism 
of the cross-reactive effects of IgA is still unknown, but 
this phenomenon is a great advantage in preventing infec-
tion. In fact, natural inﬂ  uenza virus infection was shown 
to be superior to vaccination with inactivated virus in 
inducing cross-protection against infection by mutated 
viruses within a particular subtype of the A-type virus 
in humans.10–12 Another reason why the mucosal immune 
system is adept at preventing infection is that the effector 
sites are not restricted to the originally sensitized mucosa. 
IgA-speciﬁ  c antibody forming cell (AFC) precursors 
migrate from mucosal sites throughout the entire body 
via site-speciﬁ  c homing pathways. This system is referred 
to as the common mucosal immune system.13–17 Because 
of the advantages of induction of mucosal immunity for 
preventing inﬂ  uenza, several strategies have been used 
to attempt to development a mucosal vaccine. For effec-
tive induction of secretory IgA by inactivated vaccine, 
mucosal co-administration of vaccine with adjuvant is 
necessary. As a mucosal adjuvant, a bacterial toxin such 
as cholera toxin (CT) or Escherichia coli heat-labile toxin 
(LT) have been used experimentally.18,19 Although LT 
is an effective adjuvant for the production of mucosal 
IgA, it has adverse clinical side effects, such as facial 
paralysis (Bell’s palsy).20 New, clinically safe and effec-
tive adjuvants are necessary for the administration of 
intranasal inﬂ  uenza vaccines to humans. The most prom-
ising candidate for mucosal adjuvant is PolyI:PolyC12U 
(Ampligen®), which is synthetic dsRNA and has a good 
safety proﬁ  le based on clinical trials, including a recent 
double-blind, placebo-controlled Phase III clinical trial 
for chronic fatigue syndrome (CFS).21–23 To date, 75,000 
doses of Ampligen® have been administered to humans, at 
an average dose of 400 mg, and it has been generally well 
tolerated. Recently, it was shown that PolyI:PolyC12U was 
as effective as poly(I:C) in inducing maturation of human 
monocyte-derived dendritic cells in vitro.24 So PolyI:
PolyC12U (Ampligen®) was examined as an adjuvant for 
mucosal inﬂ  uenza H5N1 vaccine administered intranasally 
in mice together with synthetic dsRNAs (poly(I:C) and 
Ampligen®) as powerful TLR-3 agonists.
Highly pathogenic avian inﬂ  uenza 
virus H5N1
The ﬁ  rst outbreak of the highly pathogenic avian inﬂ  uenza 
virus H5N1 was reported in humans and birds in Hong 
Kong in 1997, during which six out of 18 infected people 
died.25 Subsequently, re-emergence of the H5N1 virus 
associated with a high fatality rate (greater than 60%) 
has been reported in southern China, Vietnam, Thailand, 
Cambodia, Indonesia, Turkey, and Iraq. From January 
2003 to September 2008, 387 laboratory-confirmed 
human cases of H5N1 were reported to the World Health 
Organization (WHO). Although most human H5N1 Therapeutics and Clinical Risk Management 2009:5 128
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infections have been caused by the direct transmission of 
virus from infected poultry, there is fear that a pandemic 
could result if subsequent transmission of H5N1 virus 
occurred between infected humans.2 Because the abil-
ity to be transmitted from human to human represents 
the ﬁ  nal barrier to a new pandemic of H5N1, there is 
an urgent and important public health need to develop 
effective vaccines in preparation for such a pandemic. 
However developing a vaccine against the H5N1 virus 
poses a number of problems. A highly contained facility 
is required, and the virus grows very poorly in embryo-
nated eggs because it kills chickens. Attenuation of the 
vaccine strain is necessary to eliminate these problems. 
Currently licensed human vaccines are strain-speciﬁ  c and 
do not protect against heterotypic inﬂ  uenza viruses. This 
is problematic, because inﬂ  uenza A (H5N1) continues 
to evolve into antigenically distinct clades. The question 
remains of how an effective vaccine can be prepared for 
an impending pandemic of a new inﬂ  uenza, which might 
be caused by a highly pathogenic strain of avian inﬂ  uenza 
virus. Inﬂ  uenza virus A (H5N1) is not the only strain that 
could cause a new pandemic in humans.
H5 vaccine candidates must be continually updated 
to match the antigenicity of circulating viruses because 
of the differences in HA antigenicity among 1997, 2003, 
and 2004 H5 viruses.26 In addition, it is difﬁ  cult to predict 
which strain of virus (H5 or other avian-associated HA) will 
be responsible for a pandemic. In such circumstances, the 
ideal approach is to prepare a vaccine that confers strong 
cross-protective immunity against variants of a particular 
virus strain. Mucosal immunity induced through natural 
infection by inﬂ  uenza virus has potent cross-protective 
activity, compared with subcutaneous vaccination-induced 
systemic immunity. Cross-protective activity is correlated 
with mucosal secretory IgA, which is not induced after sub-
cutaneous vaccination.27 In order to induce cross-protective 
mucosal immunity through inﬂ  uenza vaccination, we have 
examined the effect of intranasal administration of an inac-
tivated viral vaccine with various adjuvants, and found that 
mucosal IgA plays an important role in cross-protection 
against variant inﬂ  uenza A and B virus infection.7,28–30 
Nicholson and colleagues reported that the H5N1 vac-
cine is poorly antigenic in humans, and requires adjuvant 
to elicit a detectable antibody response.31 Several groups 
looking at avian inﬂ  uenza H5N1 vaccines have reported that 
intranasal administration of a formalin-inactivated whole 
virus vaccine with or without mutant E. coli LT adjuvant 
(R192G), or an adenoviral vector-based inﬂ  uenza vaccine, 
protected mice from lethal challenge by a heterologous 
H5N1 virus.32–34
Development of adjuvant-combined 
inactivated nasal vaccines
Subcutaneous injection of inactivated vaccines would be an 
effective strategy in an epidemic caused by a homologous 
virus, as it induces speciﬁ  c serum IgG, but would be less 
effective in an epidemic caused by a heterologous virus. On 
the other hand, live attenuated vaccines effectively protect 
against heterologous virus infection by inducing secretory 
IgA, IgG, and cytotoxic lymphocyte (CTL) responses. 
However, because their safety has been proven only in 
healthy people between the age of 5 and 49, their use is 
approved only for this group of people in the US. Intranasal 
administration of inactivated vaccines represents a potential 
solution to overcoming these problems.
In clinical trials, inactivated whole virus particles and 
split-product vaccines have been shown to be effective in 
preventing live virus infection when administered intrana-
sally.35–39 Moreover, intranasal administration of an inac-
tivated whole virion vaccine induced a broad spectrum of 
heterosubtypic immunity in mice, which was not observed 
using an ether-split vaccine.33 The stronger immunogenicity 
of the inactivated whole virion vaccine was likely due to the 
stimulation of innate immunity by genomic single-stranded 
RNA, via TL-R7.5,40
Intranasal administration of an inactivated ether-split vac-
cine and the synthetic dsRNA poly(I:C) conferred effective 
cross-protection in the upper respiratory tract (RT) against 
viral variants (drift viruses) of inﬂ  uenza A, or B-type viruses.7 
Because most viruses produce dsRNA during replication,41 
synthetic dsRNA likely acts as a molecular mimic of viral 
infection. The mammalian TLR-3 receptor recognizes 
dsRNA, and activates the NF-κB42 pathway, resulting in 
activation of type I IFN, which in turn enhances the primary 
antibody response to subcutaneous immunization of soluble 
materials.43 This adjuvant activity of type I FN appears to 
play an important role in bridging the gap between innate 
and adaptive immunity.43
In mice, intranasal administration of an ether-split vaccine 
from PR8 (inﬂ  uenza strain H1N1) and poly(I:C) adjuvant 
induced a strong anti-HA IgA and IgG response in nasal 
washes and serum, respectively, while vaccination without 
poly(I:C) induced very little response. In addition, adminis-
tration of either an A/Beijing (H1N1) or A/Yamagata (H1N1) 
vaccine and poly(I:C) conferred complete protection against 
PR8 virus challenge in a mouse model of nasal infection, Therapeutics and Clinical Risk Management 2009:5 129
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suggesting that intranasal vaccination with poly(I:C) adjuvant 
confers cross-protection against variant viruses. Although 
the systemic antigen-speciﬁ  c T-cell responses were induced 
by intranasal vaccination with poly(I:C) adjuvant, T-cell 
responses against heterologous inﬂ  uenza viruses were weak. 
Moreover, TLR3, which is a receptor for dsRNA in nasal-
associated lymphoid tissue (NALT), was upregulated at the 
level of mRNA expression upon intranasal administration 
of a split vaccine and poly(I:C).7 Recently, a clinically safe 
dsRNA, PolyI:PolyC12U (Ampligen®), was investigated as a 
dsRNA adjuvant for intranasal avian ﬂ  u vaccines.
To evaluate the adjuvant effect of Ampligen®, the pro-
tective effect of intranasal administration of vaccine and 
Ampligen® adjuvant against homologous (A/Vietnam) 
and heterologous (A/Hong Kong and A/Indonesia) H5N1 
inﬂ  uenza virus challenge was examined44 (Figure 2). Two 
groups of mice were immunized either intranasally or sub-
cutaneously with 1 μg of vaccine from Vietnam strain and 
10 μg of Ampligen®, then challenged by intranasal admin-
istration of 1000 PFU of H5N1 inﬂ  uenza virus at 2 weeks 
after the ﬁ  nal immunization. A third group of control mice 
was immunized intranasally with 10 μg of Ampligen® 
alone. In response to homologous viral challenge, all the 
mice immunized intranasally with vaccine and Ampligen® 
completely cleared viruses in their nasal cavity. By con-
trast, signiﬁ  cantly higher levels of virus in nasal wash were 
detected in mice immunized subcutaneously with vaccine 
and Ampligen®. All mice of both groups survived after 
homologous A/Vietnam/1194/2004 viral challenge. In the 
heterologous virus challenge group, virus titers in nasal wash 
of intranasal vaccination group were signiﬁ  cantly lower than 
in the subcutaneous vaccination group after A/Hong Kong 
or A/Indonesia viral challenge. Consequently, although 
intranasally immunized mice survived a potentially lethal 
infection with A/Hong Kong or A/Indonesia viruses, most 
inﬂ  uenza-challenged mice died (Figure 2). These results 
clearly indicated that intranasal administration of H5N1 
vaccine and Ampligen® adjuvant is more effective than sub-
cutaneous vaccination against homologous and heterologous 
H5N1 inﬂ  uenza virus challenge.
BALB/c mice were immunized three times intranasally 
or subcutaneously with trivalent inactivated influenza 
vaccine licensed in Japan for the 2005–2006 season.45 
The vaccine included A/New Caledonia/20/99 (H1N1), 
A/New York/55/2004 (H3N2), and B/Shanghai/361/2002 
viral strains and was administered with PolyI:PolyC12U 
(Ampligen®) as an adjuvant. The immunized mice were 
challenged with A/Hong Kong, A/Vietnam, or A/Indonesia 
H5N1 inﬂ  uenza viruses 2 weeks after the ﬁ  nal immunization. 
Mice immunized intranasally manifested cross-reactivity of 
mucosal IgA and serum IgG with H5N1 virus as well as a 
reduced H5N1 viral titer in nasal wash, and their survival 
was higher after H5N1 virus challenge compared with 
nonimmunized animals. Subcutaneous immunization did 
not induce a cross-reactive IgA response and did not afford 
protection against H5N1 viral infection. These results sug-
gest that intranasal immunization with annual inﬂ  uenza 
vaccine may overcome the problem of a limited supply of 
H5N1 virus vaccine by providing cross-protective mucosal 
immunity in humans against H5N1 viruses with pandemic 
potential.
Cross-protection by other vaccines
Parenteral inactivated vaccines, including split-product, 
subunit vaccines and whole virion vaccines, induce mainly 
serum IgG antibodies that are weakly cross-protective against 
drift viruses within a subtype. These IgG antibodies would 
be effective against an epidemic of homologous virus, but 
would rarely be effective against an epidemic caused by a 
heterologous virus. Thus, an inactivated parenteral vaccine 
can effectively protect against an epidemic caused by a 
homologous virus, but would be relatively ineffective against 
an epidemic caused by a heterologous virus.
On the other hand, a cold-adapted, live-attenuated virus 
vaccine licensed in Russia and in the USA46–48 appeared to 
mimic the natural course of infection, and provided cross-
protective immunity against different subtypes of viruses by 
inducing secretory (S)-IgA antibodies, serum IgG antibodies, 
and a CTL response.49,50 The advantage of live viral vaccines 
is that they induce not only mucosal IgA and serum IgG 
antibody responses, but also CTL responses, and confer 
cross-protection against different subtypes of inﬂ  uenza 
virus. Current cold-adapted (ca) live-attenuated inﬂ  uenza 
virus vaccines are growth-restricted to the upper RT. Using 
reverse genetics, a live attenuated vaccine was generated 
that encodes a modiﬁ  ed form of H5 HA and wild-type-type 
N1 neuraminidase from inﬂ  uenza A virus strain H5N1, with 
the remaining gene segments derived from the cold-adapted 
(CA) inﬂ  uenza A vaccine donor strain. This vaccine was 
immunogenic in mice.51 Four weeks after receiving a single 
intranasally administered dose of CA vaccine, mice were 
fully protected from lethal challenge with homologous and 
antigenically distinct, heterologous wt strain H5N1 viruses 
from different genetic sublineages.51 Because live attenuated 
vaccine can induce immune responses equivalent to those 
induced by natural infection, a live vaccine that has no side Therapeutics and Clinical Risk Management 2009:5 130
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effects would be good candidate of pandemic vaccine, if it 
could be produced.
Conclusion
Now that a pandemic of new inﬂ  uenza virus seems possible, 
and because it will be difﬁ  cult to know when a pandemic 
will occur or which strain of virus will be the cause, it is 
in our best interests to develop broadly effective and safe 
vaccines against the inﬂ  uenza virus. For the development of 
a broadly effective vaccine, induction of mucosal immunity 
is an inevitable requirement, as mucosal secretory IgA plays 
an important role in cross-protection. Vaccines designed to 
induce mucosal immunity are necessary to combat a new 
inﬂ  uenza pandemic. As stated above, one of the requirements 
for inducing mucosal immunity is administration of the vaccine 
at mucosal sites, such as the nasal mucosa. For this reason, 
intranasal administration of inactivated vaccine plus adjuvant, 
or live attenuated vaccines, are promising candidates for 
Figure 2 H5N1 virus titers in nasal washes and survival rates after lethal challenge with homologous A/Vietnam, heterologous A/Hong Kong, or heterologous A/Indonesia 
viruses. Mice were immunized intranasally (solid bar) or subcutaneously (gray bar) with vaccine and Ampligen®, then challenged by intranasal administration of 1000 PFU of 
A/Vietnam (A), A/Hong Kong (B), or A/Indonesia (C) virus 14 days after the ﬁ  nal immunization. Nasal washes were collected three days post infection (d.p.i), and virus titers 
were measured by plaque assay. Each bar represents the mean ± SD of ﬁ  ve mice and open circles indicate individual animals. For statistical analysis, virus titers were compared 
to those from control mice (open bar) that received intranasal administration of 10 μg of Ampligen® alone. Survival rates were monitored for 18 days. Copyright © 2007. 
Reproduced with permission from Ichinohe T, Kawaguchi A, Tamura S, et al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, 
protects mice against homologous and heterologous virus challenge. Microbes Infect. 2007; 9:1333–1340.
Note: *p  0.05. 
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inducing cross-protective immunity against variant inﬂ  uenza 
viruses. However, for safety reasons, the ideal vaccine for 
induction of cross-protective mucosal immunity may be an 
inactivated vaccine. Recently, several candidate adjuvants 
that are effective in mucosal vaccine administration have 
emerged, including dsRNA (Ampligen®),7,8 CMPs, SMPs,30 
and mutant CT.52 These mucosal adjuvants represent promising 
approaches to the development of safe and effective vaccines 
for a potential inﬂ  uenza pandemic.
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